(:REPH)

Mar 21, 2022 07:00 am ET
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that...
Mar 01, 2022 04:05 pm ET
Recro Reports Fourth Quarter and Year End 2021 Financial Results
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported...
Feb 23, 2022 07:00 am ET
Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key...
Feb 22, 2022 04:05 pm ET
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that...
Jan 26, 2022 07:00 am ET
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that...
Jan 19, 2022 07:00 am ET
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the...
Jan 06, 2022 04:05 pm ET
Recro Reports Inducement Grants For New Staff
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the...
Jan 03, 2022 07:00 am ET
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that...
Dec 02, 2021 07:00 am ET
Recro to Present at Stephens Annual Investment Conference
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that...
Nov 09, 2021 04:05 pm ET
Recro Reports Third Quarter 2021 Financial Results
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported...
Nov 02, 2021 04:05 pm ET
Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that...
Oct 27, 2021 07:00 am ET
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the...
Oct 20, 2021 07:00 am ET
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that...
Oct 06, 2021 07:00 am ET
Recro Reports Inducement Grants For New Staff
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the...
Sep 21, 2021 07:00 am ET
Recro Signs Renewable Energy Agreement With Georgia Power
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, today announced the signing of a...
Sep 08, 2021 07:00 am ET
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and BioCorRx, Inc. (“BioCorRx”;...
Sep 08, 2021 07:00 am ET
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
via NewMediaWire -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges in small molecule therapeutic development, and...
Aug 17, 2021 07:00 am ET
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Aug 13, 2021 08:50 am ET
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Aug 10, 2021 07:00 am ET
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Aug 09, 2021 04:05 pm ET
Recro Reports Second Quarter 2021 Financial Results
Recro Pharma, Inc. (“Recro”; NASD:REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today reported...
Aug 02, 2021 04:05 pm ET
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Jul 20, 2021 07:00 am ET
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Jul 13, 2021 07:00 am ET
Recro Enters Development and Manufacturing Agreement With New Client
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Jul 07, 2021 07:00 am ET
Recro Reports Inducement Grants for New Staff
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Jun 16, 2021 07:00 am ET
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Jun 02, 2021 07:00 am ET
Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
May 18, 2021 07:00 am ET
Recro Enters Development Agreement With Astex Pharmaceuticals
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the...
May 14, 2021 09:15 am ET
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the...
May 12, 2021 08:30 am ET
Recro Announces Pricing of $30.0 Million Public Offering of Common Stock
Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the...
May 11, 2021 04:30 pm ET
Recro Announces Proposed Public Offering of Common Stock
Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that...
May 06, 2021 04:05 pm ET
Recro Reports First Quarter 2021 Financial Results
Recro Pharma, Inc. (“Recro”; NASD:REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today reported...
Apr 29, 2021 04:05 pm ET
Recro to Report Financial Results for First Quarter 2021 on May 6
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Apr 15, 2021 07:00 am ET
Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the...
Apr 06, 2021 07:00 am ET
Recro Reports Inducement Grants for New Staff
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the...
Apr 05, 2021 07:00 am ET
Recro Strengthens Business Development Team to Drive Customer Growth and Diversification
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Mar 02, 2021 07:00 am ET
Recro to Present at H.C. Wainwright Global Life Science Conference
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Feb 26, 2021 07:00 am ET
Recro Reports Fourth Quarter and Year End 2020 Financial Results
Recro Pharma, Inc. (“Recro”; NASD:REPH), a dedicated contract development and manufacturing organization (CDMO), solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today reported...
Feb 23, 2021 04:05 pm ET
Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Feb 23, 2021 07:00 am ET
Recro Announces Amendment to Athyrium Credit Facility
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the...
Feb 19, 2021 04:05 pm ET
Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced...
Feb 11, 2021 07:00 am ET
Recro Strengthens Leadership Team With Key Executive and Board Appointments
Recro Pharma, Inc. (“Recro”; NASD: REPH), a dedicated contract development and manufacturing organization (CDMO) solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the...
Dec 18, 2020 09:34 pm ET
Recro Grants Inducement Award to New Chief Executive Officer
Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral...
Dec 16, 2020 07:00 am ET
Recro Announces Executive Changes
Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral...
Nov 09, 2020 07:00 am ET
Recro Reports Third Quarter 2020 Financial Results
Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage...
Nov 02, 2020 07:00 am ET
Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and...
Sep 18, 2020 07:30 am ET
Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced...
Aug 10, 2020 07:00 am ET
Recro Reports Second Quarter 2020 Financial Results
Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today reported...
Aug 06, 2020 07:00 am ET
Recro to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today...
Jun 11, 2020 10:00 am ET
Recro Highlights Manufacturing Readiness For Essential Drugs and Medical Supplies
Recro Gainesville, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug...
May 13, 2020 12:44 pm ET
RECRO PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Recro Pharma, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Recro Pharma, Inc. (NASDAQ: REPH) on behalf of Recro Pharma stockholders. Our investigation concerns whether Recro Pharma has violated the federal securities laws and/or engaged in other unlawful business practices.
May 12, 2020 07:50 pm ET
INVESTOR ALERT: Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Recro Pharma, Inc.
The law firm of Kirby McInerney LLP is investigating potential claims against Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ: REPH). This investigation concerns whether Recro Pharma has violated federal securities laws and/or engaged...
May 11, 2020 05:13 pm ET
Recro Pharma, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton; Investors Who Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has launched an investigation into potential securities fraud by Recro Pharma Inc. (NASDAQ: REPH) and certain of its officers. Investors who have lost...
May 11, 2020 03:44 pm ET
Investor Alert: Kaplan Fox Investigates Recro Pharma, Inc.
NEW YORK, May 11, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Recro Pharma, Inc. ("Recro Pharma" or the "Company") (NASDAQ: REPH).  Investors who purchased Recro Pharma securities may be affected.
May 11, 2020 07:00 am ET
Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact
Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products,...
May 08, 2020 07:00 am ET
Recro to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 11, 2020
Recro Pharma, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products,...
May 01, 2020 04:05 pm ET
Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
Recro Pharma, Inc. (NASDAQ:REPH) (the “Company”), a high-performing, revenue generating contract development and manufacturing organization, today announced that due to the emerging health impact of the coronavirus pandemic, the Company has changed...
Mar 04, 2020 07:00 am ET
Recro Reports Financial Results for the Year Ended 2019
Recro Pharma, Inc. (Nasdaq:REPH), a high-performing, revenue generating contract development and manufacturing organization (CDMO), today reported financial results for the year ended December 31, 2019. “The CDMO business has continued to deliver...
Mar 02, 2020 07:00 am ET
Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020
Recro, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO) with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today...
Nov 21, 2019 04:30 pm ET
Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization
Recro Pharma, Inc. (NASDAQ:REPH), a high-performing, revenue generating contract development and manufacturing organization (CDMO), today announced that it has completed the spin out of its Acute Care segment, Baudax Bio. Baudax Bio common stock...
Nov 21, 2019 07:00 am ET
Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies
Baudax Bio, Inc. (NASDAQ:BXRX) today announced its launch as an independent, publicly traded pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings.  Beginning tomorrow,...
Nov 13, 2019 07:00 am ET
Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement
Recro Pharma, Inc. (NASDAQ:REPH), a pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that the U.S. Securities and Exchange Commission (SEC) has declared...
Nov 08, 2019 07:00 am ET
Recro Pharma Reports Third Quarter 2019 Financial Results
Recro Pharma, Inc. (NASDAQ:REPH), a pharmaceutical company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three and nine months...
Nov 05, 2019 04:05 pm ET
Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019
Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019.  Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Friday, November 8, 2019 to...
Nov 05, 2019 07:00 am ET
Recro Pharma’s Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock
Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that its board of directors has approved the planned spin-off of...
Oct 31, 2019 07:00 am ET
FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application
Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that it has received a written decision from the U.S. Food and...
Aug 08, 2019 07:14 am ET
Recro Pharma Reports Second Quarter 2019 Financial Results
Recro Pharma, Inc. (NASDAQ:REPH), a pharmaceutical company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three and six months...
Aug 01, 2019 07:00 am ET
Recro Pharma to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Recro Pharma, Inc. (NASDAQ:REPH), a pharmaceutical company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today announced that it will report second quarter financial...
May 30, 2019 07:00 am ET
Recro Pharma to Present at Upcoming Investor Conferences
Recro Pharma, Inc. (Nasdaq:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today announced that Gerri Henwood, the Company’s President and Chief...
May 10, 2019 07:00 am ET
Recro Pharma Reports First Quarter 2019 Financial Results
Recro Pharma, Inc. (NASDAQ:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today reported financial results for the three months ended March 31,...
May 06, 2019 07:00 am ET
Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019
Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Friday, May 10, 2019 to discuss...
Apr 19, 2019 07:55 am ET
Detailed Research: Economic Perspectives on GoPro, Recro Pharma, BrightView, Schmitt Industries, China XD Plastics Company, and Oxbridge Re — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GoPro, Inc. (NASDAQ:GPRO), Recro Pharma, Inc. (NASDAQ:REPH), BrightView...
Apr 16, 2019 07:00 am ET
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville
Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that Recro Gainesville LLC, its CDMO division, has amended its...
Apr 11, 2019 04:05 pm ET
Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
Recro Pharma, Inc. (Nasdaq:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) segment, today announced a moderated poster presentation highlighting new intravenous (IV)...
Apr 03, 2019 04:05 pm ET
Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company with a high-performing contract development and manufacturing (CDMO) Segment, today announced an initiative that will reduce the operating expenses of its Acute...
Mar 25, 2019 07:00 am ET
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the appointment of Arnaud Ajdler to the Company’s Board of Directors. Mr....
Mar 22, 2019 03:30 pm ET
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced it has received a second Complete Response Letter (CRL) from the U.S. Food...
Mar 12, 2019 07:00 am ET
Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced an Industry ‘Lunch and Learn’ Session at the upcoming American Academy of...
Mar 04, 2019 07:00 am ET
Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced that it has closed on an amended and expanded $125 million credit facility...
Feb 25, 2019 04:05 pm ET
Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the publication of clinical data from its Phase III study evaluating the...
Feb 20, 2019 07:00 am ET
Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the publication of new intravenous (IV) meloxicam data.  The article,...
Feb 19, 2019 07:00 am ET
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial results for the fourth quarter and year ended December 31,...
Feb 14, 2019 07:00 am ET
Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will report fourth quarter and year end financial results...
Feb 11, 2019 07:00 am ET
Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced that Recro Gainesville LLC, its contract development and manufacturing...
Jan 02, 2019 07:00 am ET
Recro Pharma Amends Athyrium Credit Facility
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced an amendment to its existing credit facility with Athyrium Capital...
Dec 21, 2018 07:00 am ET
Recro Pharma Amends IV Meloxicam License Agreement with Alkermes
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced an amendment to its global licensing agreement with Alkermes Pharma...
Dec 10, 2018 07:00 am ET
Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicam’s Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced a poster presentation highlighting intravenous (IV) meloxicam’s effect...
Nov 16, 2018 08:20 am ET
Detailed Research: Economic Perspectives on StarTek, Plantronics, Akoustis Technologies, Genie Energy, Recro Pharma, and BIO-key International — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of StarTek, Inc. (NYSE:SRT), Plantronics, Inc. (NYSE:PLT), Akoustis...
Nov 14, 2018 07:00 am ET
Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase II clinical data for...
Nov 08, 2018 07:00 am ET
Recro Pharma to Participate in Upcoming Investor Conferences
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that Recro Pharma management will participate in the following upcoming...
Nov 07, 2018 07:00 am ET
Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial results for the three months and nine months ended September...
Oct 31, 2018 07:00 am ET
Recro Pharma to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will report third quarter financial results on Wednesday,...
Oct 08, 2018 07:00 am ET
Recro Pharma Announces PDUFA Date for IV Meloxicam
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal...
Oct 01, 2018 07:00 am ET
Recro Announces Expansion of CDMO Service Capabilities
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the opening of an expanded 24,000 square foot GMP development and high...
Sep 10, 2018 07:00 am ET
Recro Pharma to Participate in Upcoming Investor Conferences
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that Recro Pharma management will participate in the following upcoming...
Sep 05, 2018 07:00 am ET
Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced three poster presentations at PAINWeek 2018, taking place September 4-8,...
Sep 04, 2018 07:00 am ET
Recro Pharma Provides Regulatory Update for IV Meloxicam
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today provided a regulatory update following receipt of the official meeting minutes...
Aug 07, 2018 07:00 am ET
Recro Pharma Reports Second Quarter 2018 Financial Results
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial results for the three months and six months ended June 30,...
Jul 31, 2018 07:00 am ET
Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will report second quarter financial results on Tuesday, August...
Jul 30, 2018 11:19 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAL, QCOM, REVG, FLKS and REPH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 29, 2018 11:00 am ET
SHAREHOLDER ALERT: TAL ORA REVG FPI NWL PCG REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 27, 2018 08:55 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH)
Glancy Prongay Murray LLP (“GPM”) reminds investors of the July 30, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ: REPH)...
Jul 27, 2018 02:41 pm ET
CLASS ACTION UPDATE for ORA and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 26, 2018 03:13 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MRCY, REVG and REPH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 26, 2018 01:27 pm ET
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Recro Pharma, Inc. (“Recro Pharma” or “the Company”) (NASDAQ:
Jul 25, 2018 04:45 pm ET
CLASS ACTION UPDATE for FIZZ, ACAD and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 25, 2018 11:57 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAL, ANW, DB, FIZZ and REPH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 24, 2018 04:00 pm ET
CLASS ACTION UPDATE for QCOM, FLR, FPI and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 24, 2018 11:00 am ET
SHAREHOLDER ALERT: ATEN ANW DB QCOM FPI FIZZ SBGL ACAD FLR REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 23, 2018 06:43 pm ET
The Law Offices of Howard G. Smith Reminds Investors of July 30th Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH)
Law Offices of Howard G. Smith reminds investors of the July 30, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ: REPH) securities between July 31, 2017, and May 23, 2018, inclusive
Jul 23, 2018 01:57 pm ET
CLASS ACTION UPDATE for ATEN, FLR and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 23, 2018 01:22 pm ET
Important Stockholder Deadline Alert in Class Action Lawsuit Filed Against Recro Pharma, Inc. by Kaskela Law LLC
Kaskela Law LLC has filed a class action lawsuit against Recro Pharma, Inc. (NASDAQ:REPH) (“Recro” or the “Company”) on behalf of investors who purchased or acquired the Company’s securities between July 31, 2017 and May 23, 2018, inclusive (the...
Jul 23, 2018 12:15 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ORA, REPH, FLR, FIZZ, NWL and PCG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 22, 2018 05:20 pm ET
CLASS ACTION UPDATE for QCOM, REPH and PCG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 20, 2018 09:05 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the July 30, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ:
Jul 20, 2018 05:10 pm ET
CLASS ACTION UPDATE for COOL, REPH and SBGL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 19, 2018 01:00 pm ET
SHAREHOLDER ALERT – MFGP ATEN REPH DB QCOM TAL NWL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 19, 2018 10:30 am ET
REPH EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Recro Pharma, Inc.; Upcoming Deadline- REPH
NEW YORK, July 19, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Recro Pharma, Inc. (NASDAQ: REPH) from July 31, 2017 through May 23, 2018, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for Recro Pharma investors under the federal securities laws.
Jul 18, 2018 04:08 pm ET
CLASS ACTION UPDATE for MFGP REPH and HAIR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 18, 2018 02:47 pm ET
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of REPH, ANW, DB and QCOM
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 18, 2018 01:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – REPH
Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ:REPH) and certain of its officers.   The class action, filed in United States District Court, Eastern District of...
Jul 17, 2018 11:14 am ET
SHAREHOLDER ALERT – PPG ATEN REPH REVG UNM HAIR GOGO COOL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 16, 2018 05:11 pm ET
CLASS ACTION UPDATE for PPG and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 15, 2018 12:00 am ET
SHAREHOLDER ALERT – PRTA SYMC PPG MFGP FLR ATEN REPH DB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 13, 2018 12:53 pm ET
SHAREHOLDER ALERT – HAIR GOGO COOL MD GLCNF GLNCY ATEN REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 12, 2018 04:04 pm ET
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SYMC, MFGP, FLR, REPH, and ORA
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 12, 2018 01:48 pm ET
SHAREHOLDER ALERT – ATEN REPH REVG SBGL MRCY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 11, 2018 07:44 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Recro Pharma, Inc. Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ: REPH) between July 31, 2017, and May 23, 2018, inclusive (the “Class Period”). Recro Ph
Jul 11, 2018 02:12 pm ET
CLASS ACTION UPDATE for REVG and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 11, 2018 10:00 am ET
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline – July 30, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC reminds investors that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ:REPH) and certain of its officers, on behalf of shareholders who...
Jul 09, 2018 06:06 pm ET
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PPG, MFGP, REPH, REVG and PCG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 09, 2018 03:18 pm ET
SHAREHOLDER ALERT – PPG MFGP FLR ATEN REPH DB ANW REVG: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 06, 2018 04:47 pm ET
REPH LOSS ALERT: Rosen Law Firm Reminds Recro Pharma, Inc. Investors of Important July Deadline in Suit – REPH
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Recro Pharma, Inc. (NASDAQ:REPH) from July 31, 2017 through May 23, 2018, both dates inclusive (the “Class Period”) of the important July 30, 2018 lead...
Jul 06, 2018 10:51 am ET
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ESPR, ORA, MFGP, FLR, and REPH
The Klein Law Firm reminds investors that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jul 05, 2018 01:00 pm ET
CLASS ACTION UPDATE for FLR, REPH, DB and REVG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 04, 2018 08:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – REPH
Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ: REPH) and certain of its officers. The class action, filed in United States District Court, Eastern District of Pennsylvania, and docketed under 18-cv-02279, is on behalf of a class consisting of investors who purchased or otherwise, acquired securities of Recro securities between July 31, 2017 through May 23, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations
Jul 03, 2018 01:00 pm ET
CLASS ACTION UPDATE for PRTA, MFGP, and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jul 02, 2018 01:03 pm ET
SHAREHOLDER ALERT – LC ESPR INWK FLEX KLIC SYMC MFGP FLR REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 29, 2018 07:41 pm ET
SHAREHOLDER DEADLINE ALERT: INWK FLEX SYMC PPG FLR REPH ORA NWL GOGO; Johnson Fistel Reminds Investors of Important Class Action Deadlines
SAN DIEGO, June 29, 2018 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP announces that class actions have been commenced on behalf of shareholders of the following companies and herby notifies investors of the following impending deadlines:
Jun 29, 2018 05:45 pm ET
RECRO LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Recro Pharma, Inc. To Contact The Firm
Faruqi Faruqi, LLP, a leading national securities law firm, reminds investors in Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ:REPH) of the July 30, 2018 deadline to seek the role of lead plaintiff in a federal securities class action...
Jun 28, 2018 03:00 pm ET
SHAREHOLDER ALERT – GOGO INWK FLEX SYMC REPH ORA TAL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 28, 2018 01:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – REPH
Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ: REPH) and certain of its officers. The class action, filed in United States District Court, Eastern District of Pennsylvania, and docketed under 18-cv-02279, is on behalf of a class consisting of investors who purchased or otherwise, acquired securities of Recro securities between July 31, 2017 through May 23, 2018, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations
Jun 27, 2018 02:52 pm ET
UPCOMING DEADLINES: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KLIC, REPH, ANW, and PCG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 26, 2018 02:27 pm ET
SHAREHOLDER ALERT – FLR REPH TAL HAIR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 26, 2018 07:00 am ET
Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase III clinical data for...
Jun 23, 2018 09:00 am ET
REPH TICKER ALERT: Rosen Law Firm Reminds Recro Pharma, Inc. Investors of Important Deadline in Lawsuit– REPH
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Recro Pharma, Inc. (NASDAQ: REPH) from July 31, 2017 through May 23, 2018, both dates inclusive (the “Class Period”) of the important July 30, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Recro Pharma investors under the federal securities laws.
Jun 22, 2018 04:00 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Recro Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 30, 2018 – REPH
The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Recro Pharma, Inc. ("Recro Pharma") (NASDAQ:REPH) between July 31, 2017 and May 23, 2018. You are...
Jun 20, 2018 06:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - REPH
NEW YORK, June 20, 2018 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ:  REPH) and certain of its officers.   The class action, filed in United States District Court, Eastern District of Pennsylvania, and docketed under 18-cv-02279, is on behalf of a class consisting of investors who purchased or otherwise, acquired securities of Recro securities between July 31, 2017 through May 23, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the fede
Jun 20, 2018 06:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline - REPH
NEW YORK, June 20, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ:  REPH) and certain of its officers.   The class action, filed in United States District Court, Eastern District of Pennsylvania, and docketed under 18-cv-02279, is on behalf of a class consisting of investors who purchased or otherwise, acquired securities of Recro securities between July 31, 2017 through May 23, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of t
Jun 18, 2018 04:36 pm ET
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Actions Involving Macquarie Infrastructure Corporation, InnerWorkings, Inc., Micro Focus International plc, Recro Pharma,
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 16, 2018 11:00 am ET
REPH LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Recro Pharma, Inc.– REPH
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Recro Pharma, Inc. (NASDAQ: REPH) from July 31, 2017 through May 23, 2018, both dates inclusive (the...
Jun 16, 2018 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Recro Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – REPH
Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ:REPH) and certain of its officers.  The class action, filed in United States District Court, Eastern District of...
Jun 15, 2018 07:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of Micro Focus International plc, Recro Pharma, Inc., Aegean Marine Petroleum Network Inc.
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 14, 2018 12:13 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Recro Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 30, 2018 – REPH
The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Recro Pharma, Inc. ("Recro Pharma") (NASDAQ:REPH) between July 31, 2017 and May 23, 2018. You are...
Jun 13, 2018 03:47 pm ET
REPH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Recro Pharma, Inc. and a Lead Plaintiff Deadline of July 30, 2018
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Recro Pharma, Inc. ("Recro") (NASDAQ:REPH)...
Jun 08, 2018 02:22 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Recro Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 30, 2018 – REPH
The following statement is being issued by Levi Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Recro Pharma, Inc. ("Recro Pharma") (NASDAQ:REPH) between July 31, 2017 and May 23, 2018. You are...
Jun 08, 2018 10:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline – July 30, 2018
Attorney Advertising -- Bronstein, Gewirtz Grossman, LLC notifies investors that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ:REPH) and certain of its officers, on behalf of shareholders who...
Jun 07, 2018 03:00 pm ET
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Recro Pharma, Inc. (REPH)
The Klein Law Firm announces the commencement of an investigation of Recro Pharma, Inc. (NASDAQCM:REPH) concerning possible violations of federal securities laws.
Jun 06, 2018 05:18 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Recro Pharma, Inc. Investors (REPH)
National law firm Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ: 
Jun 06, 2018 05:00 pm ET
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Recro Pharma, Inc. (REPH)
The Klein Law Firm announces the commencement of an investigation of Recro Pharma, Inc. (NASDAQCM:REPH) concerning possible violations of federal securities laws.
Jun 05, 2018 02:46 pm ET
REPH INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Recro Pharma, Inc.
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQCM: REPH) violated federal securities laws.
Jun 05, 2018 12:59 pm ET
Robbins Arroyo LLP: Recro Pharma, Inc. (REPH) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Recro Pharma, Inc. (NasdaqCM: REPH) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between July 31, 2017 and May 23, 2018. Recro is a sp
Jun 05, 2018 09:00 am ET
Kaskela Law LLC Files Investor Class Action Lawsuit Against Recro Pharma, Inc.
Kaskela Law LLC has filed an investor class action lawsuit against Recro Pharma, Inc. (NASDAQ:REPH) (“Recro” or the “Company”) on behalf of all investors who purchased or acquired the Company’s securities between July 31, 2017 and May 23, 2018,...
Jun 05, 2018 07:30 am ET
REPH INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Recro Pharma, Inc. Investors
Law Offices of Howard G. Smith continues its investigation on behalf of Recro Pharma, Inc. (“Recro Pharma” or the “Company) (NASDAQ: REPH) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jun 04, 2018 06:30 pm ET
INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Recro Pharma, Inc. (''Recro Pharma” or ''the Company'') (NASDAQ:
Jun 04, 2018 04:15 pm ET
REPH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Recro Pharma, Inc.
The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQCM:REPH) violated federal securities laws.
Jun 04, 2018 10:30 am ET
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Recro Pharma, Inc. Investors (REPH)
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ:
Jun 03, 2018 05:00 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Recro Pharma, Inc.
Levi & Korsinsky announces it has commenced an investigation of Recro Pharma, Inc. (“Recro” or “the Company”) (NASDAQCM: REPH) concerning possible violations of federal securities laws.
Jun 01, 2018 04:44 pm ET
RECRO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Recro Pharma, Inc. To Contact The Firm
NEW YORK, June 1, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ: REPH).
Jun 01, 2018 03:39 pm ET
REPH INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Recro Pharma, Inc. Investors
Law Offices of Howard G. Smith announces that it has commenced an investigation on behalf of Recro Pharma, Inc. (“Recro Pharma” or the “Company) (NASDAQ: REPH) investors concerning the Company and its officers’ possible violations of federal securities laws.
Jun 01, 2018 03:17 pm ET
Kaskela Law LLC Files Shareholder Class Action Lawsuit Against Recro Pharma, Inc.
Kaskela Law LLC has filed a shareholder class action lawsuit against Recro Pharma, Inc. (NASDAQ: REPH) (“Recro” or the “Company”) on behalf of investors who purchased or acquired the Company’s securities between July 31, 2017 and May 23, 2018, inclusive (the “Class Period”).
Jun 01, 2018 12:17 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Recro Pharma, Inc.
Levi & Korsinsky announces it has commenced an investigation of Recro Pharma, Inc. (“Recro” or “the Company”) (NASDAQCM: REPH) concerning possible violations of federal securities laws.
Jun 01, 2018 10:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline - July 30, 2018
NEW YORK, June 1, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ: REPH) and certain of its officers, on behalf of shareholders who purchased Recro securities between July 31, 2017 through May 23, 2018, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/reph.
May 31, 2018 07:18 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Recro Pharma, Inc. – REPH
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Recro Pharma, Inc. (NASDAQ: REPH) from July 31, 2017 through May 23, 2018, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Recro Pharma investors under the federal securities laws.
May 31, 2018 06:02 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Recro Pharma, Inc. and Certain Officers – REPH
Pomerantz LLP announces that a class action lawsuit has been filed against Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ:REPH) and certain of its officers.   The class action, filed in United States District Court, Eastern District of...
May 30, 2018 02:06 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Recro Pharma, Inc. Investors (REPH)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ:
May 30, 2018 10:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Recro Pharma, Inc. (REPH)
NEW YORK, May 30, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ: REPH). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/reph.
May 25, 2018 03:50 pm ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Recro Pharma, Inc.
Kaskela Law LLC is investigating Recro Pharma, Inc. (NASDAQ: REPH) (“Recro” or the “Company”) on behalf of the Company’s shareholders. The investigation concerns whether Recro and certain of its officers and/or directors have violated the federal securities laws.
May 25, 2018 12:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Recro Pharma, Inc. - REPH
NEW YORK, May 25, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Recro Pharma, Inc. ("Recro" or the "Company") (NASDAQ: REPH).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
May 24, 2018 07:00 am ET
Recro Pharma Receives Complete Response Letter from the FDA
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and...
May 09, 2018 07:00 am ET
Recro Pharma Reports First Quarter 2018 Financial Results
Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for  the hospital and other acute care settings, today reported financial results for the three months ended March 31, 2018. “During...
May 07, 2018 07:00 am ET
Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the receipt of issue notifications for three patents covering...
May 02, 2018 04:05 pm ET
Recro Pharma Announces Commercial Team Additions
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for  the hospital and other acute care settings, today announced the expansion of its team through the appointment of two new employees...
May 02, 2018 07:00 am ET
Recro Pharma to Report First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9, 2018
Conference Call and Webcast Scheduled for Wednesday, May 9, 2018 at 8:00 a.m. ET
Apr 30, 2018 07:00 am ET
Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
MALVERN, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that a poster highlighting preclinical data for...
Apr 16, 2018 07:00 am ET
Recro Pharma to Present IV Meloxicam Data at the 43rd Annual Regional Anesthesiology and Acute Pain Medicine Meeting
MALVERN, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced eight poster presentations at the 43rd Annual Regional...
Mar 29, 2018 04:05 pm ET
Recro Pharma Announces Commercial Team Additions
MALVERN, Pa., March 29, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for  the hospital and other acute care settings, today announced the expansion of its  team through the...
Mar 27, 2018 07:00 am ET
Recro Pharma Announces Publication of Phase III IV Meloxicam Bunionectomy Data in the Clinical Journal of Pain
MALVERN, Pa., March 27, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of Phase III clinical data...
Mar 21, 2018 07:00 am ET
Recro Pharma to Present at the 17th Annual Needham Healthcare Conference
MALVERN, Pa., March 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, the Company’s President and Chief...
Mar 06, 2018 07:00 am ET
Recro Pharma to Present at Upcoming Investor Conferences
MALVERN, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that Recro Pharma management will present at...
Mar 05, 2018 07:00 am ET
Recro Pharma Announces an Educational Symposium on Challenges in Acute Pain Management and Advances in Evidence-Based Management Approaches at the American Academy of Orthopaedic Surgeons 2018 Annual
MALVERN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced an Industry ‘Lunch and Learn’ Session on...
Mar 02, 2018 04:05 pm ET
Recro Pharma Announces Commercial Team Additions
MALVERN, Pa., March 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced the expansion of its acute care commercialization team...
Feb 27, 2018 07:00 am ET
Recro Pharma Reports Year End 2017 Financial Results
IV Meloxicam NDA Submitted and PDUFA Action Date Set for May 26, 2018
Feb 21, 2018 07:00 am ET
Recro Pharma to Host Analyst and Investor Day on February 28, 2018
MALVERN, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will host an Analyst and...
Feb 20, 2018 07:00 am ET
Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Bunionectomy Data in the Journal of Pain Research
MALVERN, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase II...
Feb 02, 2018 07:00 am ET
Recro Pharma Announces Key Sales Team Additions
MALVERN, Pa., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the expansion of its acute care commercialization...
Jan 17, 2018 08:45 am ET
Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology
MALVERN, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase II...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.